Dihydroergotamine monomethanesulfonate
Dihydroergotamine monomethanesulfonate Brand names, Dihydroergotamine monomethanesulfonate Analogs
- Agit
- Angionorm
- D.H.E.
- D.H.E. 45
- DET MS
- DHE-45
- Dergotamine
- Diergo
- Dihidroergotamina [INN-Spanish]
- Dihydergot
- Dihydroergotamine mesylate
- Dihydroergotamine methanesulfonate
- Dihydroergotamine monomethanesulfonate
- Dihydroergotaminum [INN-Latin]
- Dirgotarl
- Endophleban
- Ergomimet
- Ergont
- Ergotamine, 9,10-dihydro-
- Ergotonin
- Ikaran
- Migranal
- Morena
- Orstanorm
- Tonopres
- Verladyn
Dihydroergotamine monomethanesulfonate Brand Names Mixture
- No information avaliable
Dihydroergotamine monomethanesulfonate Chemical_Formula
C33H37N5O5
Dihydroergotamine monomethanesulfonate RX_link
http://www.rxlist.com/cgi/generic2/dihyergmes.htm
Dihydroergotamine monomethanesulfonate fda sheet
Dihydroergotamine monomethanesulfonate msds (material safety sheet)
Dihydroergotamine monomethanesulfonate Synthesis Reference
No information avaliable
Dihydroergotamine monomethanesulfonate Molecular Weight
583.678 g/mol
Dihydroergotamine monomethanesulfonate Melting Point
No information avaliable
Dihydroergotamine monomethanesulfonate H2O Solubility
No information avaliable
Dihydroergotamine monomethanesulfonate State
Solid
Dihydroergotamine monomethanesulfonate LogP
No information avaliable
Dihydroergotamine monomethanesulfonate Dosage Forms
Liquid
Dihydroergotamine monomethanesulfonate Indication
For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
Dihydroergotamine monomethanesulfonate Pharmacology
Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.
Dihydroergotamine monomethanesulfonate Absorption
Interpatient variable and may be dependent on the administration technique
Dihydroergotamine monomethanesulfonate side effects and Toxicity
Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
Dihydroergotamine monomethanesulfonate Patient Information
PATIENT INFORMATIOn
Follow the link below to get detailed information before taking D.H.E. 45� (dihydroergotamine mesylate) Injection.
http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm
Follow the link below to get detailed information before taking D.H.E. 45� (dihydroergotamine mesylate) Injection.
http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm
Dihydroergotamine monomethanesulfonate Organisms Affected
Humans and other mammals
